SCHEMBL25079595

SCHEMBL25079595

CCC(c1ccccc1)C(c1ccc(C)cc1)c1ccc(O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.60
LMNA P02545 4/20 0.60
CYP1A2 P05177 1/20 0.60
PGR P06401 1/20 0.60
CHRM2 P08172 1/20 0.60
CYP3A4 P08684 1/20 0.60
ADORA3 P0DMS8 1/20 0.60
AR P10275 1/20 0.60
CYP2D6 P10635 1/20 0.60
MAPT P10636 1/20 0.60
CHRM1 P11229 1/20 0.60
CYP2C9 P11712 1/20 0.60
ALOX15 P16050 1/20 0.60
DRD1 P21728 1/20 0.60
TBXA2R P21731 1/20 0.60
PTGS1 P23219 1/20 0.60
SLC6A2 P23975 1/20 0.60
CYP2C19 P33261 1/20 0.60
ADRA1A P35348 1/20 0.60
OPRM1 P35372 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18926564 0.85 ESR1 (0.83) ESR1LMNACYP1A2PGRCHRM2
P-Cresol SCHEMBL28072492 0.81 ACHE (0.56) ESR1LMNACYP1A2PGRCHRM2
Hexestrol SCHEMBL17628536 0.81 ESR1 (0.83) ESR1LMNACYP1A2PGRCHRM2
SCHEMBL3861713 0.81 HKDC1 (0.55) ESR1LMNACYP1A2PGRCHRM2
Ammonia Solution, Strong SCHEMBL18191766 0.79 HKDC1 (0.53) ESR1LMNACYP1A2PGRCHRM2
P-Cresol SCHEMBL28213196 0.79 ACHE (0.48) ESR1LMNACYP1A2PGRCHRM2
SCHEMBL12049665 0.77 ACHE (0.56) ESR1LMNACYP1A2PGRCHRM2
SCHEMBL1151700 0.77 ESR1 (0.47) ESR1LMNACYP1A2PGRCHRM2
SCHEMBL735987 0.77 ACHE (0.68) ESR1LMNACYP1A2PGRCHRM2
SCHEMBL20763933 0.77 ACHE (0.68) ESR1LMNACYP1A2PGRCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023023531-A1 ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2023-02-23 WO disclosed